Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58-Reference-Cited by-同舟云学术

Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

Published:2020-09-22 Issue:1 Volume:23 Page:29-38
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Cahn Avivit¹²^ORCID,Wiviott Stephen D.³,Mosenzon Ofri¹²^ORCID,Murphy Sabina A.³,Goodrich Erica L.³,Yanuv Ilan¹,Rozenberg Aliza¹,Wilding John P. H.⁴^ORCID,Leiter Lawrence A.⁵^ORCID,Bhatt Deepak L.³^ORCID,McGuire Darren K.⁶,Litwak Leon⁷,Kooy Adriaan⁸^ORCID,Gause‐Nilsson Ingrid A. M.⁹,Fredriksson Martin⁹,Langkilde Anna Maria⁹,Sabatine Marc S.³^ORCID,Raz Itamar¹²^ORCID

Affiliation:

1. Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center Jerusalem Israel

2. Faculty of Medicine, Hebrew University of Jerusalem Israel

3. Division of Cardiovascular Medicine TIMI Study Group, Brigham and Womenʼs Hospital and Harvard Medical School Boston Massachusetts

4. Department of Cardiovascular and Metabolic Medicine Institute of Life Course and Medical Sciences, University of Liverpool Liverpool UK

5. Department of Medicine Li Ka Shing Knowledge Institute, St. Michaelʼs Hospital, University of Toronto Toronto Canada

6. Division of Cardiology, Department of Internal Medicine University of Texas Southwestern Medical Center, and Parkland Health and Hospital System Dallas Texas

7. Endocrinology Unit, Diabetes Section Hospital Italiano de Buenos Aires Buenos Aires Argentina

8. University Medical Center Groningen and Bethesda Diabetes Research Center Groningen the Netherlands

9. BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14179

Reference39 articles.

1. IDF Diabetes Atlas. 9th ed.https://diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf. Accessed February 10 2020.

2. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

3. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

4. Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials

5. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?;Frontiers in Endocrinology;2024-06-27

2. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial;Nature Medicine;2024-06-24

3. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease;Diabetes, Obesity and Metabolism;2024-05-19

4. Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria;Circulation;2023-11-12

5. Combination therapy with kidney protective therapies: optimizing the benefits?;Current Opinion in Nephrology & Hypertension;2023-09-28